The cluster headache syndrome market size has grown strongly in recent years. It will grow from $0.75 billion in 2023 to $0.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to an increase in public health initiatives, advancements in research and development for headache treatments, heightened awareness of neurological disorders, expansion of multinational clinical trials, and greater availability of supportive therapies.
The cluster headache syndrome market size is expected to see strong growth in the next few years. It will grow to $1.04 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of neurological disorders, growing investments in the development of new drugs, higher healthcare spending, a rising number of depression cases, and an increase in drug approvals. Major trends for this period include technological advancements, telemedicine, personalized medicine, neuromodulation techniques, and targeted drug therapies.
The increasing prevalence of neurological disorders is anticipated to drive the growth of the cluster headache syndrome market. Neurological disorders encompass a range of conditions affecting the nervous system, including the brain, spinal cord, and nerves throughout the body. The rise in neurological disorders is influenced by factors such as the growing prevalence of risk factors such as diabetes, improved diagnostic capabilities, neurological complications from other conditions, and socioeconomic disparities. Treatments for neurological disorders can help manage cluster headache syndrome, as some of these conditions overlap with or impact headache pathways. Addressing the symptoms and underlying factors of cluster headaches can effectively reduce their frequency, severity, and impact. For instance, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that 10.5 million Europeans were affected by dementia (a neurological disorder), with this number expected to rise to 18.7 million by 2050. Therefore, the growing prevalence of neurological disorders is driving the cluster headache syndrome market.
Leading companies in the cluster headache syndrome market are focusing on developing advanced technologies, such as implantable neurostimulation systems, to offer more effective treatment options. Implantable neurostimulation technology involves surgically implanted devices that deliver electrical impulses to specific areas of the nervous system. For example, in May 2021, Unity HA, a US-based medical device company, launched the Pulsante SPG Microstimulator System for treating acute pain associated with chronic cluster headaches. Approved by the Food and Drug Administration (FDA), this innovative implantable device features advanced neurostimulation techniques specifically designed to target the neural pathways related to cluster headaches, providing a more precise and effective pain management solution. The device is minimally invasive, with a small, implantable unit that can be discreetly placed and adjusted as needed.
In October 2022, Emergex Vaccines Holding Limited, a UK-based biotechnology company, acquired the assets of Zosano Pharma Corporation, including intellectual property, license agreements, and manufacturing equipment, for an undisclosed amount. This acquisition enables Emergex to utilize Zosano's microneedle patch technology and manufacturing capabilities. Zosano Pharma Corporation is a US-based clinical-stage biopharmaceutical company specializing in developing treatments for cluster headache syndrome.
Major companies operating in the cluster headache syndrome market are Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals, Grünenthal GmbH, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Zogenix Inc., Neurelis Inc., ElectroCore Medical LLC, Ceruvia Lifesciences, TrioxBio Inc., Winston Pharmaceuticals Inc., Zosano Pharma Corporation, Autonomic Technologies Inc., H. Lundbeck A/S.
North America was the largest region in the cluster headache syndrome market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cluster headache syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cluster headache syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cluster headache syndrome is a condition marked by severe, recurrent headaches that occur in clusters or episodes. These headaches are typically one-sided and extremely painful, often described as sharp, burning, or piercing sensations. They usually manifest around the eye or temple area and last between 15 minutes and three hours.
The main types of cluster headache syndrome are episodic and chronic. Episodic cluster headache features relatively long, pain-free remissions between headache episodes and is the more common type, affecting about 90% of those with the condition. Various medications used to treat cluster headaches include calcium channel blockers, corticosteroids, sumatriptan, lithium carbonate, ergots, melatonin, anti-seizure drugs, and local anesthetics. Diagnosis may involve neurological examination, magnetic resonance imaging (MRI), and computed tomography (CT) scans. Treatments can be administered orally, topically, intravenously, and through other methods, and are available through channels such as hospital pharmacies, retail pharmacies, online stores, and more.
The cluster headache syndromes market research report is one of a series of new reports that provides cluster headache syndromes market statistics, including cluster headache syndromes industry global market size, regional shares, competitors with a cluster headache syndromes market share, detailed cluster headache syndromes market segments, market trends, and opportunities, and any further data you may need to thrive in the cluster headache syndromes industry. This cluster headache syndromes research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cluster headache syndrome market consists of revenues earned by entities by providing services such as clinical services, specialized consultations, patient education programs, and support services. and related medical devices, microneedle patch technology, and diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The cluster headache syndrome market also includes sales of abortive medication, fast-acting analgesics, calcium channel blockers, corticosteroids, and anticonvulsants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cluster headache syndrome market size is expected to see strong growth in the next few years. It will grow to $1.04 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of neurological disorders, growing investments in the development of new drugs, higher healthcare spending, a rising number of depression cases, and an increase in drug approvals. Major trends for this period include technological advancements, telemedicine, personalized medicine, neuromodulation techniques, and targeted drug therapies.
The increasing prevalence of neurological disorders is anticipated to drive the growth of the cluster headache syndrome market. Neurological disorders encompass a range of conditions affecting the nervous system, including the brain, spinal cord, and nerves throughout the body. The rise in neurological disorders is influenced by factors such as the growing prevalence of risk factors such as diabetes, improved diagnostic capabilities, neurological complications from other conditions, and socioeconomic disparities. Treatments for neurological disorders can help manage cluster headache syndrome, as some of these conditions overlap with or impact headache pathways. Addressing the symptoms and underlying factors of cluster headaches can effectively reduce their frequency, severity, and impact. For instance, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that 10.5 million Europeans were affected by dementia (a neurological disorder), with this number expected to rise to 18.7 million by 2050. Therefore, the growing prevalence of neurological disorders is driving the cluster headache syndrome market.
Leading companies in the cluster headache syndrome market are focusing on developing advanced technologies, such as implantable neurostimulation systems, to offer more effective treatment options. Implantable neurostimulation technology involves surgically implanted devices that deliver electrical impulses to specific areas of the nervous system. For example, in May 2021, Unity HA, a US-based medical device company, launched the Pulsante SPG Microstimulator System for treating acute pain associated with chronic cluster headaches. Approved by the Food and Drug Administration (FDA), this innovative implantable device features advanced neurostimulation techniques specifically designed to target the neural pathways related to cluster headaches, providing a more precise and effective pain management solution. The device is minimally invasive, with a small, implantable unit that can be discreetly placed and adjusted as needed.
In October 2022, Emergex Vaccines Holding Limited, a UK-based biotechnology company, acquired the assets of Zosano Pharma Corporation, including intellectual property, license agreements, and manufacturing equipment, for an undisclosed amount. This acquisition enables Emergex to utilize Zosano's microneedle patch technology and manufacturing capabilities. Zosano Pharma Corporation is a US-based clinical-stage biopharmaceutical company specializing in developing treatments for cluster headache syndrome.
Major companies operating in the cluster headache syndrome market are Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals, Grünenthal GmbH, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Zogenix Inc., Neurelis Inc., ElectroCore Medical LLC, Ceruvia Lifesciences, TrioxBio Inc., Winston Pharmaceuticals Inc., Zosano Pharma Corporation, Autonomic Technologies Inc., H. Lundbeck A/S.
North America was the largest region in the cluster headache syndrome market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cluster headache syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cluster headache syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cluster headache syndrome is a condition marked by severe, recurrent headaches that occur in clusters or episodes. These headaches are typically one-sided and extremely painful, often described as sharp, burning, or piercing sensations. They usually manifest around the eye or temple area and last between 15 minutes and three hours.
The main types of cluster headache syndrome are episodic and chronic. Episodic cluster headache features relatively long, pain-free remissions between headache episodes and is the more common type, affecting about 90% of those with the condition. Various medications used to treat cluster headaches include calcium channel blockers, corticosteroids, sumatriptan, lithium carbonate, ergots, melatonin, anti-seizure drugs, and local anesthetics. Diagnosis may involve neurological examination, magnetic resonance imaging (MRI), and computed tomography (CT) scans. Treatments can be administered orally, topically, intravenously, and through other methods, and are available through channels such as hospital pharmacies, retail pharmacies, online stores, and more.
The cluster headache syndromes market research report is one of a series of new reports that provides cluster headache syndromes market statistics, including cluster headache syndromes industry global market size, regional shares, competitors with a cluster headache syndromes market share, detailed cluster headache syndromes market segments, market trends, and opportunities, and any further data you may need to thrive in the cluster headache syndromes industry. This cluster headache syndromes research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cluster headache syndrome market consists of revenues earned by entities by providing services such as clinical services, specialized consultations, patient education programs, and support services. and related medical devices, microneedle patch technology, and diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The cluster headache syndrome market also includes sales of abortive medication, fast-acting analgesics, calcium channel blockers, corticosteroids, and anticonvulsants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cluster Headache Syndrome Market Characteristics3. Cluster Headache Syndrome Market Trends and Strategies32. Global Cluster Headache Syndrome Market Competitive Benchmarking33. Global Cluster Headache Syndrome Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cluster Headache Syndrome Market
4. Cluster Headache Syndrome Market - Macro Economic Scenario
5. Global Cluster Headache Syndrome Market Size and Growth
6. Cluster Headache Syndrome Market Segmentation
7. Cluster Headache Syndrome Market Regional and Country Analysis
8. Asia-Pacific Cluster Headache Syndrome Market
9. China Cluster Headache Syndrome Market
10. India Cluster Headache Syndrome Market
11. Japan Cluster Headache Syndrome Market
12. Australia Cluster Headache Syndrome Market
13. Indonesia Cluster Headache Syndrome Market
14. South Korea Cluster Headache Syndrome Market
15. Western Europe Cluster Headache Syndrome Market
16. UK Cluster Headache Syndrome Market
17. Germany Cluster Headache Syndrome Market
18. France Cluster Headache Syndrome Market
19. Italy Cluster Headache Syndrome Market
20. Spain Cluster Headache Syndrome Market
21. Eastern Europe Cluster Headache Syndrome Market
22. Russia Cluster Headache Syndrome Market
23. North America Cluster Headache Syndrome Market
24. USA Cluster Headache Syndrome Market
25. Canada Cluster Headache Syndrome Market
26. South America Cluster Headache Syndrome Market
27. Brazil Cluster Headache Syndrome Market
28. Middle East Cluster Headache Syndrome Market
29. Africa Cluster Headache Syndrome Market
30. Cluster Headache Syndrome Market Competitive Landscape and Company Profiles
31. Cluster Headache Syndrome Market Other Major and Innovative Companies
35. Cluster Headache Syndrome Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Cluster Headache Syndrome Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cluster headache syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cluster headache syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Episodic; Chronic2) By Drug Type: Calcium Channel Blockers; Corticosteroids; Sumatriptan; Lithium Carbonate; Ergots; Melatonin; Anti-Seizure; Local Anesthetics
3) By Diagnosis: Neurological Examination; Magnetic Resonance Imaging; Computed Tomography Scan
4) By Route of Administration: Oral; Topical; Intravenous; Other Routes Of Administration
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Stores; Other Distribution Channels
Key Companies Mentioned: Pfizer Inc.; Bayer AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Bayer AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals
- Grünenthal GmbH
- Mallinckrodt Pharmaceuticals
- Upsher-Smith Laboratories
- Zogenix Inc.
- Neurelis Inc.
- ElectroCore Medical LLC
- Ceruvia Lifesciences
- TrioxBio Inc.
- Winston Pharmaceuticals Inc.
- Zosano Pharma Corporation
- Autonomic Technologies Inc.
- H. Lundbeck A/S
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | September 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 0.8 Billion |
Forecasted Market Value ( USD | $ 1.04 Billion |
Compound Annual Growth Rate | 6.8% |
Regions Covered | Global |